Orignal Post here
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)
QR-421a observed to be well tolerated with no serious adverse events reported
Two pivotal Phase 2/3 trials are expected to start by the end of 2021
Management to host a conference call today at 8:15am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass.,
Read Loss of sight is a grief for those who experience it. We must then be able to escape from the gloomy clutches of depression.
Read On his website and personal blog, Giuseppe di Grande made an interesting roundup of the “bullshit”, as he defines it, that students, companies and startups have invented in recent years for the blind.
Read February is the low vision awareness month.
We wrote about this in this article.
This year we want to celebrate this month dedicated to low vision awareness with music.
Read Since 2000, the Pantone Color Institute has chosen the “Color of The Year” every year.
Having become a real pop culture phenomenon, the announcement of the color of the year by the Pantone Color Institute attracts the attention of the world design landscape every year and tries to convey an iconic message to billions of color addicts.
Read Original post on www.healthline.com
The interior designer and co-host of “Nate & Jeremiah by Design” shares his ideas for home updates that can make spaces safer — without sacrificing style — for people with vision loss.
Read The annual observance of the International Day of Disabled Persons was proclaimed in 1992 by United Nations General Assembly resolution 47/3.
Read A few days ago we shared a post about Paint it Yellow, a spin-off of #YellowTheWorld by Girl Scout Troop 1673.
Read Watch the video presentation with Caption or in ASL here
You can also download the script.
Presentation Summary:
A presentation updating the Usher community of ProQR’s continued clinical progress.
Read 